Consequently, downregulation of TARBP2 enhances sorafenib resistance through stabilization of the Nanog protein in HCC cells and is correlated with poor clinical outcomes in HCC patients (Fig. 7). The gene discussed is TARBP2; the disease is hepatocellular carcinoma.